세계의 CAR-T 세포 치료 시장 : 시장 규모, 점유율, 동향 - 제품별, 표적 항원별, 적응증별, 인구통계별, 최종 사용자별, 지역별 예측(-2029년)
CAR T-cell Therapy Market Size, Share & Trends by Product, Target Antigen, Indication, Demographic, End User & Region - Global Forecast to 2029
상품코드:1519291
리서치사:MarketsandMarkets
발행일:2024년 07월
페이지 정보:영문 266 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 CAR-T 세포 치료 시장 규모는 2024년 55억 달러에서 2029년 290억 달러에 이를 것으로 추정되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 39.6%가 될 것으로 보입니다.
시장 성장의 원동력은 세계의 암 이환율의 상승입니다. CAR-T 세포 치료의 기술적 진보, 치료 개발에 대한 투자 및 자금 조달 증가는 시장 성장을 가속할 것으로 보입니다. 그러나 CAR-T 세포 치료과 관련된 부작용과 고가의 치료 비용은 예측 기간 동안 시장 성장을 억제할 것으로 예상되는 주요 요인의 일부입니다.
조사 범위
조사 대상년도
2022년-2029년
기준년
2023년
예측 기간
2024년-2029년
검토 단위
금액(10억 달러)
부문별
제품별, 표적 항원별, 적응증별, 인구통계별, 최종 사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양의, 라틴아메리카의, 중동 및 아프리카의
제품별로 2023년에는 예수카르타 부문이 가장 큰 시장 점유율을 차지했습니다. 시장 성장의 요인은 재발/난치성 암 치료에서 Yescarta의 높은 주효율과 지속적인 관해가 치료 채용 증가로 이어졌습니다는 것입니다.
최종 사용자별로 세계의 CAR-T 세포 치료 시장은 병원, 장기 요양 시설, 전문센터로 구분됩니다. 2023년에는 병원 부문이 세계의 CAR-T 세포 치료 시장의 주요 촉진요인으로 부상하여 예측 기간 동안 가장 높은 복합 연간 성장률(CAGR)을 나타냈습니다. 병원은 CAR-T 세포 치료을 표준 종양학 치료 프로토콜에 통합합니다. 이러한 경향은 CAR-T 세포 치료를 받아들이는 병원이 증가함에 따라 CAR-T 세포 치료에 대한 수요를 높이고 있습니다. 또한, 병원은 CAR-T 세포 치료의 임상시험을 촉진하는 데 중요한 역할을합니다. 연구 이니셔티브 및 제약 기업과의 제휴에 적극적으로 참여함으로써 병원은 증거 기반 확대 및 규제 당국의 승인 촉진에 기여하고 시장 성장을 가속하고 있습니다.
본 보고서에서는 세계의 CAR-T 세포 치료 시장에 대해 조사했으며, 제품별, 표적 항원별, 적응증별, 인구통계별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리 있습니다.
GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD(HEDY GROUP CO., LTD.)
CARTESIAN THERAPEUTICS, INC.
AUTOLUS THERAPEUTICS
ALLOGENE THERAPEUTICS
CRISPR THERAPEUTICS
WUGEN
제14장 부록
BJH
영문 목차
영문목차
The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.
Scope of the Report
Years Considered for the Study
2022-2029
Base Year
2023
Forecast Period
2024-2029
Units Considered
Value (USD Billion)
Segments
By Product, By Target, By Indication, By Demographic & By End User
Regions covered
North America, Europe, the Asia Pacific, Latin America and the Middle East & Africa
"Yescarta segment accounted for the highest share of 2023."
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.
"The Hospitals End User segment held the dominant share in the CAR T-cell therapy market."
Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.
"Asia Pacific region estimated to show fastest growth rate."
The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific's progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 70%, and Demand Side - 30%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
List of Companies Profiled in the Report:
Bristol-Myers Squibb Company (US)
Gilead Sciences Inc. (US)
Novartis AG (Switzerland)
Johnson & Johnson (US)
CARsgen Therapeutics Holdings Limited (China)
IASO Biotherapeutics (China)
JW (Cayman) Therapeutics Co. Ltd (China)
ImmunoAct (India)
CRISPR Therapeutics (Switzerland)
Autolus Therapeutics (UK)
Allogene Therapeutics (US)
Cartesian Therapeutics Inc. (US)
Guangzhou Bio-gene Technology Co. Ltd (China)
Wugen (US).
Research Coverage:
This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
Market Development: Comprehensive information about lucrative markets - the report analyses the CAR T-cell therapy market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE ASSUMPTIONS
2.3.1 CAGR PROJECTIONS
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 VOLUME ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH LIMITATIONS
2.7 STUDY ASSUMPTIONS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CAR T-CELL THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT
4.4 CAR T-CELL THERAPY MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing cancer prevalence
5.2.1.2 Technological advancements in CAR T-cell therapies
5.2.1.3 Rising investment and funding for therapy development
